

# Metabolomics in nonalcoholic fatty liver disease - a new technique for an open horizon

<sup>1,2</sup>Dana A. Crişan, <sup>1,3</sup>Corina I. Radu, <sup>1</sup>Alina M. Suci, <sup>4</sup>Florina Romanciuc, <sup>4</sup>Carmen Socaciu, <sup>3</sup>Mircea Grigorescu

<sup>1</sup> Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania; <sup>2</sup> Clinical Municipal Hospital, Cluj-Napoca, Romania; <sup>3</sup> Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania; <sup>4</sup> Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania.

**Abstract.** The diagnosis of nonalcoholic fatty liver disease (NAFLD), the detection of non-alcoholic steatohepatitis (NASH) and the assessment of prognosis of this widespread disease is a permanent lately preoccupation of researches from different medical fields: hepatology, metabolic disease, diabetes, cardiology. Some biological techniques tried to have an insight over the pathophysiology of the steatosis, revealing important but insufficient data regarding this disease. Profiling the metabolomics products is a new emergent technique that promises to reveal some unknown aspects in NAFLD field. Data from mass spectrometry and nuclear magnetic resonance spectroscopy combined with statistical modeling have permitted the authors to analyze and interpret metabolic signatures in terms of metabolic pathways and protein interaction networks. We review here the metabolomics data found for different stages of NAFLD: first for simple steatosis, then for NASH which associates inflammation, and finally, for fibrosis and cirrhosis that brings about complications with high morbidity and mortality, hoping that this new technique will increase the knowledge in diagnosing and treating NAFLD.

**Key Words:** steatosis, NASH, metabolomics, fibrosis.

**Copyright:** This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Corresponding Author:** C. I. Radu, email: drcorinaradu@gmail.com

## Introduction

The spectrum of fatty liver disease comprises different aspect of the disease starting with simple steatosis passing to non-alcoholic steatohepatitis (NASH), which can add different stages of fibrosis, up to cirrhosis (Michelotti et al 2013). Nonalcoholic fatty liver disease (NAFLD) is assessed morphologically, if simple steatosis without hepatocyte injury (ballooning) in present, while NASH is defined by the presence of steatosis associating inflammation and ballooning, with or without fibrosis (Chalasanani et al 2012). The prevalence of NAFLD can reach 46% in developed nations (Farrell et al 2012) and affects both children and adults (Torres et al 2012). In Romania, a study conducted in 2008 on 3005 patients, revealed a prevalence of NAFLD of 20% (Radu et al 2008).

A diagnosis of NAFLD implies an increased risk of related diseases as cardiovascular disease, diabetes, colonic adenomas, hypothyroidism, and polycystic ovary syndrome (Torres et al 2012). The impact of morbidity and economic burden is significant as NAFLD has a high prevalence among liver diseases in the Western countries. As a consequence, it has been reported an increasing proportion of patients with fatty liver who undergo liver transplantation (15%–20%) (Newsome et al 2012). Diagnosis, staging and prognosis of NAFLD and NASH remain the most important challenges in this field (Jepsen et al 2011). Imaging techniques (ultrasound and magnetic resonance) are the most reliable methods for the diagnosis of NAFLD, but liver biopsy stays as gold standard of diagnosis (Oh et al 2008;

Kleiner et al 2005). Un desirable face of the imaging techniques is the procedure cost and the lack of specificity especially when the assessment of steatohepatitis and fibrosis staging are the main goals. Neither liver biopsy does not lack drawbacks, as it is expensive, subjective and invasive procedure, encumbered by different complications and sampling error (Ratziu et al 2005). The detection of fibrosis can be assessed using (transient) elastography (Castera et al 2006) or serum biomarkers combined in different panels (FibroTest) (Poynard et al 2004; Imbert-Bismut et al 2004).

The issue becomes mode difficult when the target is the detection and staging of steatosis. The biological non-invasive methods are lacking accuracy in diagnosing steatohepatitis and fibrosis in patients with fatty liver, even if there have been some attempts (ELF test, NAFLD fibrosis score) (Morra et al 2003; Guha et al 2008; Guha&Rosenberg 2008).

Offering a holistic and noninvasive approach, the emergent method called metabolomics gives a new perspective of diagnosis and staging in NAFLD. This new technique brings the advantage of identifying hundreds of metabolites characteristic for different diseases. Metabolomics is particularly suitable for the assessment of liver injury, given that the most widely used samples for testing are serum or urine, compared to other diseases like cancer, where tissue is available for different types of analysis as transcriptomics and proteomics (Barr et al 2010). The metabolic changes revealed through targeted analysis will be speculated for the detection of new potential biomarkers for fatty liver diagnosis and treatment.

Metabolomics seems to offer the advantage of being less dependent on species than gene or protein markers, allowing a direct comparison with animal models and shortcutting the way of applying in practice what the lab research shows (Heijne *et al* 2005).

## Aim

We aimed to review the importance of metabolomics in diagnosing and staging NAFLD and its progressive form – NASH. In addition, we also aimed to analyze the metabolomics value in staging liver fibrosis associated to NAFLD.

## NAFLD

Considering that this technique is relatively new described, we found few data regarding the accuracy of metabolomics in diagnosing and staging NAFLD in humans. There are, however, more studies on animal model that might create an image of the metabolomic profile modified in fatty liver. A brief presentation of the results found in international databases for metabolomics aspects in NAFLD is summarized below (adapted after Beyoğlu&Idle 2013, Dumas *et al* 2014):

- Barr *et al* 2010 - Subjects and tissue: human serum; Platform: UPLC; Up-regulated: Arachidonic acid, PC, LPC (24:0)NASH vs. NAFLD: PC(14:0/20:4), LPC (18:1); Down-regulated: FAs: 20:2n6, 18:3n3/18:3n6, LPCs, SMs, TDCA, TCDCA, DG (18:0/22:6)NASH vs. NAFLD:LPC (24:0)

- Puri *et al* 2009 - Subjects and tissue: human plasma; Platform: HPTLC – LCMS; Up-regulated metabolites: Triacylglycerols, FAs, 15-HETE Myristic acid, palmitic acid, myristoleic acid, palmitoleic acid, vaccenic acid, oleic acid, g-linolenic acid, stearidonic acid, docosapentaenoic acid. Progression from NAFLD to NASH: lipoxygenase metabolites, arachidonic acid; 5-HETE, 8-HETE, and 15-HETE. NASH specific: 11-HETE

- Cobbold *et al* 2009, Kalhan *et al* 2011 - Subjects and tissue: human plasma; Platform: UPLC-ESITQMS, GCMS LC/gas chromatography–MS. Up-regulated: GCA, TCA, GCDCA, 4:0-carnitine, glutamate, tyrosine, lactate; to differentiate NAFLD from NASH: N-acetylthreonine, aspartate, glutamate, phenylalanine, tyrosine, 3-(4-hydroxyphenyl)-lactate, kynurenine, isoleucine, leucine, valine, ornithine, glutamyl-valine,  $\gamma$ -glutamyl-(leucine, phenylalanine, tyrosine), erythronate, mannose, glucose, pyruvate, lactate, 2-oxoglutarate, carnitine, propionylcarnitine, butyrylcarnitine, 2-methylbutyrylcarnitine, GCA, TCA, GCDCA, xanthine, urate, pseudouridine, erythritol; Down-regulated: Cysteine, glutathione, disulfide, LPC (18:1), cortisone, uridine. NAFLD vs NASH: N-acetylglycine, betaine, histidine, phenylacetate, indolepropionate, 2-aminobutyrate, cysteine-glutathione 2-hydroxypalmitate, 3-carboxy-4-methyl-5-propyl-2-furanpropanoate, glycerophosphocholine, LPCs, cortisone, threonate, hippurate, catechol sulfate, indoleacrylate, 3-phenylpropionate

- Toye *et al* 2007 - Subjects and tissue: human and mice serum; Platform: NMR; Up-regulated: lactate NAFLD: lactate, glutamate; Down-regulated: glucose, choline, TMAO, betaine, VLDL

- Soga *et al* 2011 - Subjects and tissue: human serum; Platform: Serum capillary electrophoresis (CE)-MS; Up-regulated: Glucosamine, methionine sulfoxide, g-L-glutamyl-L (taurine, alanine, leucine, valine, glutamate, glycine, lysine, arginine, -serine, threonine, histidine, phenylalanine, methionine,

glutamine, citrulline); Down-regulated: L-asparagine, L-taurine, L-aspartate, g-butyrobetaine, creatinine, L-proline, L-threonine, L-phenylalanine, citrulline, L-lysine, L-serine, L-alanine, L-histidine, L-valine, L-leucine, L-tryptophan, L-methionine - Barr 2012 - Subjects and tissue: human serum; Platform: Serum capillary electrophoresis (CE)-MS; Up-regulated: Diacylglycerophosphoinositol, monoetherglycerophosphoethanolamine, monoacylglycerophosphoethanolamine, sphingoid, sphingomyelin

- Li *et al* 2011 - Subjects and tissue: mice serum; Platform: 1H NMR; Up-regulated: Lactate, glutamine, glutamate, creatine, methionine, alanine, acetate, lysine, arginine. NAFLD vs NASH: Tauro- $\beta$ -muricholate, TCA, 12-HETE, LPCs; Down-regulated: VLDL, LDL, glucose, pyruvate, N-acetyl-glycine, leucine, phosphorylcholine, choline, TMAO, betaine. NASH: LPCs

- Meikle& Christopher 2011 - Subjects and tissue: human plasma; Up-regulated: monounsaturated/unsaturated fatty acid ratio - D9-steraroyl-coA-desaturase (SCD) (adaptive but insufficient response), changes in polyunsaturated Fas and peroxisome dysfunction lipoxygenase, 15-lipoxygenase products (HETE) - Dumas *et al* 2006 - Subjects and tissue: mice serum; Up-regulated: choline, TMA, TMAO, dimethylamine, methylamine; Down-regulated: creatine, glycerate, isovalerate, pyruvate

- Sunny *et al* 2015 - Subjects and tissue: human and mice plasma; Platform: NMR based metabolic flux analysis; Up-regulated: BCAA, long chain acylcarnitines

- Männistö *et al* 2015 - Subjects and tissue: human serum; Platform: NMR analysis; Up-regulated: NASH vs normal: leucine. Simple steatosis vs NASH: alanine, histidina, phenylalanine, tyrosine, leucine; Down-regulated - Simple steatosis vs NASH: ketone bodies (betahydroxybutyrate, acetoacetate), citrate - Pastore *et al* 2014 - Subjects and tissue: human plasma (pediatric); Platform: HPLC; Up-regulated: homocysteine, cysteine and cysteinylglycine; Down-regulated: glutathione. NASH specific: homocysteine, cysteine

The lipidomic profile, briefly presented above, points some important aspects. There are metabolites that are increased in NAFLD, like phospho-choline, choline, betaine (Toye 2007, Li 2011).

This observation indicates that there is an increased turnover of phosphatidylcholine and phosphatidylethanolamine species in the liver, free fatty acids being released through the action of phospholipases A1 and A2. There is a variety of types of fatty acids depending on chain length, saturation pattern and lipid oxidation in NAFLD. The increased ratio of fatty acids indicates increased activity of different enzymes from desaturase type and peroxisome dysfunction. These results suggest that de novo lipogenesis is implied in NAFLD development. Furthermore, there are studies that showed an inflammatory status in steatosis, especially linked to the progression from NAFLD to NASH, indicating that lipogenesis associated with NAFLD and NASH is directly involved in the production of free fatty acids with lipotoxic properties which goes hand in hand with synthesis of inflammatory lipids (eicosanoids) (Puri *et al* 2009; Meikle *et al* 2011).

Fatty acids, if not catabolized by  $\beta$ -oxidation, will be stored in the liver as triacylglycerols (Vinaixa *et al* 2010, van Ginneken *et al* 2007, Hyde *et al* 2010). Therefore, the observation that fatty liver is not just storage of fat in the liver but rather a rearrangement of lipids in the liver, might be true (van Ginneken *et al*

2007). Some types of triacylglycerols TG(44:2) and TG(48:3) are massively increased in the liver (2427% and 1198%, respectively) as it has been described in an animal model. These types of triacylglycerols are frequently found in adipose tissue and these observations suggest that adipose tissue may be a source of triacylglycerols deposited in the liver in NAFLD (van Ginneken *et al* 2007). Secondly, elevated hepatic concentrations of various lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), and phosphatidylcholine (PC) species have been reported for human steatotic vs. non-steatotic livers (Garcia-Canaveras *et al* 2011).

These molecules are obvious candidates for the elevated choline and choline metabolites discussed above. One common finding is the increased level of lipid species in serum/plasma, such as triacylglycerols (Puri *et al* 2009; Vinaixa *et al* 2010; van Ginneken *et al* 2007; Hyde *et al* 2010), diacylglycerols (Vinaixa *et al* 2010), cholesterol esters (van Ginneken *et al* 2007; Hyde *et al* 2010), sphingomyelins (Vinaixa *et al* 2010), various bile salts (Barr *et al* 2010, Kalhan *et al* 2011, Garcia-Canaveras *et al* 2011), together with lactate (Toye *et al* 2007; Li *et al* 2011) and glutamate (Li *et al* 2011; Noguchi *et al* 2011). In addition, cysteine-glutathione disulfide and both oxidized and reduced glutathione (GSH) were all reported to be depressed in the liver and serum/plasma (Kalhan *et al* 2011, Garcia-Canaveras *et al* 2011). The level of glucose has been reported to be low in subjects with food deprivation used to induce liver steatosis, but not all the studies are in agreement in this respect (Toye *et al* 2007; Li *et al* 2011; Griffin *et al* 2007).

These observations together with increased level of lactate, pyruvate and alanine might suggest that NAFLD engages in cytosolic glycolysis and oxidative stress (Toye *et al* 2007; Li *et al* 2011). Soga *et al* revealed another group of serum markers for detecting NAFLD: g-glutamyl dipeptides. The presence of g-glutamyl dipeptides indicates increased GSH synthesis as a mark of oxidative stress response (Soga *et al* 2011). Under oxidizing conditions, the pool of GSH decreases; as a consequence, the activity of g-glutamyl-cysteine-synthetase increases, leading to g-glutamyl-cysteine formation. Excess of g-glutamyl-cysteine is metabolized by g-glutamyl-transpeptidase, which catalyzes the substitution of cysteine with amino acids, and the synthesis of different g-glutamyl dipeptides, released afterwards into the bloodstream. These findings are important as serum levels of g-glutamyl-transpeptidase together with aminotransferases are routinely assessed in patients with liver diseases, especially in alcoholic and nonalcoholic steatohepatitis (Soga *et al* 2011; Griffin *et al* 2007).

The metabolism of BCAA is also modified in NAFLD. A study including human and animal model demonstrated a link between BCAA and tri-carboxylic acid (TCA) cycle, reflecting hepatic insulin resistance. Insulin stimulation revealed a strong relationship between human plasma BCAA and insulin resistance. Further more, human plasma BCAA are positively correlated with long chain acylcarnitines, indicating the modulation of mitochondrial metabolism by BCAA. The authors concluded that BCAA are essential to mediate mitochondrial TCA cycle, the impairment of BCAA metabolism, contributing to mitochondrial dysfunction in NAFLD (Sunny *et al* 2015).

A very important and constant observation in different studies conducted on NAFLD is the increased level of bile acids in

serum/plasma (Barr *et al* 2010; Kalhan *et al* 2011). Bile acids act as signaling molecules in the liver implied in lipid and glucose homeostasis (Wei *et al* 2009). Certain bile acids, in particular chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA), are endogenous ligands that activate the farnesoid X receptor (FXR) (Wang *et al* 1999). The nuclear receptor FXR interferes with the conversion of cholesterol to bile acids (Torres *et al* 2012). The observation that NAFLD exists in the presence of increased serum/plasma concentrations of glycocholate, taurocholate, glycochenodeoxycholate (Kalhan *et al* 2011) and deoxycholate (Barr *et al* 2010) is at least interesting if not surprising.

## NASH

NASH is a special form of NAFLD, with progressive capacity due to a major inflammatory component (Farrell *et al* 2012). NAFLD may switch to NASH, but more than 80% of cases will remain at simple steatosis with no or minimal progression to cirrhosis and a very low risk of death (Torres *et al* 2012). It has been estimated that >11% of NASH cases will develop cirrhosis in 15 years. The inflammation involved in steatohepatitis is still a good subject for research, even though there are some authors suggesting that visceral adipose tissue has a pro-inflammatory compound (Farrell *et al* 2012). Puri *et al* showed that eicosanoids and products of oxidation of the inflammatory arachidonic acid by lipoxygenase are particularly affected during the progression from NAFLD to NASH (Puri *et al* 2009). The investigators showed that, among eicosanoids, an increase of lipoxygenase products (hydroxyeicosatetraenoic acids (HETE)) contribute to inflammation and that 11-HETE is specific to NASH (Puri *et al* 2009).

There are relatively few metabolomic studies targeting the NASH pathophysiology and the aspects that segregate NASH from NAFLD. As with NAFLD, triacylglycerols and several fatty acids were elevated in plasma (Cobbald *et al* 2009) and several other fatty acids and LPC were decreased in plasma (Kalhan *et al* 2011). Other authors reported modifications in only three phospholipids (Toye *et al* 2007). Glucose, glutamate and taurine were found to be raised in NASH in a study developed using NMR, which does not have the power to detect a large range of molecules (Toye *et al* 2007; Li *et al* 2011). An important point of view over the NASH pathogenesis was brought by a study combining metabolomics with genetics (Tanaka *et al* 2012). In this study, NASH was generated in mice fed a methionine- and choline-deficient (MCD) diet. UPLC-ESI-TOFMS metabolomics revealed a statistically significant decrease of LPC (16:0), LPC (18:0) and LPC(18:1) in serum with a significant increase in tauro-b-muricholate, taurocholate, and 12-HETE for MCD fed mice compared to mice on a normal diet. When comparing the subjects with a positive control formed genetically obese ob/ob mice with severe steatosis and severe induced inflammation, the authors observed the same changes in LPCs and bile acids as the MCD fed mice. Thus, the decline in serum LPC and rise in serum bile acids is a signature of the inflammatory component of NASH, rather than the steatotic component. To further investigate the mechanisms involved in the changes of LPC and bile acid homeostasis mentioned above in the NASH model, hepatic mRNA levels were determined by qPCR for genes involved in the metabolism and transport of LPC, bile acids and 12-HETE. It was observed an up-regulation of lysophosphatidylcholine

Table 1. Metabolomics for the assessment of fibrosis in NALFD (adapted after Beyoğlu *et al* 2013)

Subjects and tissue	Platform	Up-regulated	Down-regulated
Rat urine (Gou <i>et al</i> 2013)	GCMS	Propionate and leucine	
Human serum (Gao <i>et al</i> 2009)	NMR	Acetate, pyruvate, glutamine, “N-acetylglycoproteins”, 2-oxoglutarate, taurine, glycerol, tyrosine, 1-methylhistidine, phenylalanine	LDL, VLDL, leucine, isoleucine, valine, acetoacetate, choline, unsaturated lipid
Human serum (Waldhler <i>et al</i> 2011)	GCxGCTOFMS	D-alanine, D-proline	L-alanine, L-valine, L-isoleucine, L-leucine, L-serine, L-asparagine
Human serum (Lian <i>et al</i> 2011)	UPLC-ESIQTOFMS	GCDCA, GCA, L-acetylcarnitine, myristamide, oleamide	LPCs, myristamide, oleamide
Human serum (Lin <i>et al</i> 2011)	LCMS	16:1-carnitine, 18:1-carnitine	carnitine, pimeloylcarnitine PE (22:6/16:0), PE (20:4/18:0)
Human feces (Huang <i>et al</i> 2013)	UPLC-ESIQTOFMS	LPC (16:0), LPC (18:0), LPC (18:1), LPC (18:2)	CDCA, 7-ketolithocholic acid, urobilin, urobilinogen
Human serum (Du <i>et al</i> 2011)	LCMS	GCDCA	LPCs
Human (pediatric) plasma (Pastore <i>et al</i> 2014)	HPLC	homocysteine, cysteine	

Abbreviations: PA, palmitic acid; OA, oleic acid; NMR, nuclear magnetic resonance spectroscopy; HPTLC, high performance thin-layer chromatography; LCMS, liquid chromatography–mass spectrometry; GCFID, gas chromatography with flame ionization detection; UPLC, ultra-performance liquid chromatography; ESI, electrospray ionization; TQMS, triple quadrupole mass spectrometry; QTOFMS, quadrupole time-of-flight mass spectrometry; TMAO, trimethylamine N-oxide; TG, triacylglycerol (triglyceride); FA, fatty acid; 15-HETE, (±)-15-hydroxy5Z,8Z,11Z,13E-eicosatetraenoic acid (non-enzymic oxidation product of arachidonic acid); DCA, deoxycholic acid; GCA, glycocholic acid; TCA, taurocholic acid; GCDCA, glycochenodeoxycholic acid; TCDCa, taurochenodeoxycholic acid; LPC, lysophosphocholine; SCD1; BCA, brach chain amino acids; VLDL, Very-low-density lipoprotein; LDL, low-density lipoprotein. LC, liver cirrhosis; CHB, chronic hepatitis B; TMA, trimethylamine; CCl<sub>4</sub>, carbon tetrachloride; UFA, unsaturated fatty acid units (-CH = CH-CH<sub>2</sub>-). GCxGC-TOFMS, Twodimensional gas chromatography time-of-flight mass spectrometry. OPLS-DA, orthogonal partial least squares projection to latent structures-discriminant analysis, PE, phosphatidylethanolamine.

acyltransferases (LPCATs) which are responsible for the conversion of LPC to PC in the NASH model (Zhao *et al* 2008; Tanaka *et al* 2012).

As described on animal model, similar changes have been observed in NASH patients (Cobbold *et al* 2009; Kalhan *et al* 2011), suggesting the mechanisms are not different in humans. Finally, it should be stated that biomarkers for NASH are limited and therapeutic options are poorly developed, which emphasizes the need for further metabolomic research in this area. Levels of ketone bodies were analyzed in NASH in an important recent study on human model. Ketones proved to be decreased in patients with NASH compared to simple steatosis. Lower levels of β-OHB were associated with NASH predicting score. The authors suggested that lower levels of ketone bodies in patients with NASH reflect a decrease in the metabolism of ketone body in NASH (Männistö *et al* 2015).

Different authors confirmed the importance of liver in sulfur metabolism, although the status of plasma thiols in NAFLD is a matter of debate. In a study on human pediatric population analyzing plasma thiols, the level of homocysteine (Hcy), cysteine (Cys), cysteinyl glycine were increased in NAFLD patients, whereas GSH levels were decreased in NAFLD patients. On the contrary, patients with steatohepatitis exhibited lower levels of homocysteine and cysteine than subjects without. Taken together, these data demonstrated a defective hepatic sulfur metabolism in children with NAFLD (Constantinou *et al* 2007).

## Fibrosis

The consequence of any inflammatory process in the liver is the occurrence of fibrosis. When this connective tissue determines septa and hepatic nodules, it can be considered a cirrhotic stage. The oxidative stress is the one who initiates and entertains the inflammatory reactions involved in the occurrence of fibrosis (Yeh *et al* 2007). Liver steatosis and especially NASH are considered lately an important cause of chronic liver disease that generates cirrhosis, among other well known etiologies like alcohol, hepatic B and C viruses (Yeh *et al* 2007). The interest of researches in finding noninvasive techniques for the diagnosis of fibrotic stage and for detecting early cirrhosis is increasing lately. A lot of imagery techniques and serum markers were studied, most of them lacking a clear value to distinguish between each stage of fibrosis, (Wiegand *et al* 2013) other being prohibitive because of the cost. In this case, the new metabolomic technique needs to be tested for the accuracy of detecting fibrosis. There are few studies published on this subject, some of them found to be representative are presented in table 1.

Some studies conducted on animal model used different types of inducing cirrhosis and finally concluded that there are no major changes in urinary metabolome in cases of cirrhosis determined in healthy rats compared to cirrhosis occurred on fatty liver (Constantinou *et al* 2007; Gou *et al* 2013; Zhang *et al* 2013). In rats treated with thyoacetamide, liver extract showed higher

levels of lactate, suggesting anaerobic metabolism (Constantinou *et al* 2007), while in rats treated with carbon tetrachloride and also a hepatotoxic medicinal plant (scoparone) it has been observed a decrease in urinary aminoacids and gut flora metabolites (Gou *et al* 2013; Zhang *et al* 2013).

Metabolomic studies performed on human subjects analyzing serum or feces do not show very clear and congruent data. Still, an increased serum concentration of non-essential amino acids (Gao *et al* 2009) and some D-amino acids (Waldhler *et al* 2011) has been reported, while other essential amino acids had decreased serum concentration. This observation is in accordance with the already reported impairment in metabolizing proteins and amino acids of cirrhotic patients (Gao *et al* 2009; Waldhler *et al* 2011; Lian *et al* 2011). Other studies observed a decrease of LPCs in the serum of cirrhotic subjects with virus B or alcohol etiology (Qi *et al* 2012). The data can be extrapolated to NASH, as the pattern is similar. As far as biliary acids are concerned, a high concentration of glycochenodeoxycholic acid and glycocholic acid were observed in the serum of cirrhotic subjects (Qi *et al* 2012).

As the impairment of ammonium detoxification in cirrhosis is well known, the metabolomics confirms this modification through the shift from hepatic glutamine to glucose and glutamine (Martinez-Granados *et al* 2011).

Another metabolic chain found to be modified in cirrhosis was the reduced serum carnitine and increased serum palmitoleoylcarnitine and oleoylcarnitine concentrations (Lin *et al* 2011). An interesting observation regarding metabolomic changes in cirrhotic patients was reported related to a modification in patients' feces (Huang *et al* 2013). The authors reported an increased concentration of major LPCs in cirrhosis and a decreased excretion of chenodeoxycholic acid and 7-ketolithocholic acid, similar metabolic changes being reported also in NALFLD. Concurrently, similar metabolomics changes have been reported in cirrhotic patients, detected in serum this time, with an increased level of biliary acids and decreased level of LPCs (Du *et al* 2011).

In a study on human pediatric population analyzing plasma thiols, increased levels of Hcy and Cys were found in patients with NAFLD. A positive correlation was observed between Hcy and Cys and the presence of fibrosis in children with NAFLD. High levels of Hcy and Cys probably correlate with a pattern of more severe histological liver damage, due to mechanisms that require further studies (Pastore *et al* 2014).

## Conclusion

Metabolomic technique seems to be appropriate and useful for the diagnosis and assessment of different forms of NAFLD. A very important aspect is the detection of the progressive form of fatty liver (NASH) and the assessment of prognosis especially related to the stage of fibrosis. In a non-expensive and holistic manner, the emergent technique of metabolomics is a promising method to analyze this disease.

## Acknowledgement

This paper was published under the frame of European Social Fund, Human Resources Development Operational Programme 2007-2013, project no. POSDRU/159/1.5/S/138776.

## References

- Barr J, Caballeria J, Martínez-Arranz I, *et al*. Obesity dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. *J Proteome Res* 2012;11:2521–2532.
- Barr J, Vázquez-Chantada M, Alonso C, *et al*. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. *J Proteome Res* 2010;9(9):4501-12.
- Beyoğlu D, Idle JR. The metabolomic window into hepatobiliary disease. *J Hepatol* 2013;59(4):842-58.
- Castera L, Foucher J, Bertet J, Couzigou P, de Ledinghen V. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. *Hepatology* 2006;43(2):373-4.
- Chalasan N, Younossi Z, Lavine JE, *et al*. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012;142:1592–1609.
- Cobbold JFL, Anstee QM, Goldin RD, *et al*. Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. *ClinSci* 2009;116:403–413.
- Constantinou MA, Theocharis SE, Mikros E. Application of metabolomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats. *Toxicol Appl Pharmacol* 2007;218:11–19.
- Du Z, Zhang L, Liu S. Application of liquid chromatography-mass spectrometry in the study of metabolic profiling of cirrhosis in different grades. *Se Pu* 2011;29:314–319.
- Dumas ME, Kinross J, Nicholson JK. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. *Gastroenterology* 2014;146(1):46-62.
- Dumas M-E, Barton RH, Toye A, *et al*. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. *Proc Natl Acad Sci U S A* 2006;103:12511–12516.
- Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an inflammatory disorder: pathogenic prognostic and therapeutic implications. *Gut Liver* 2012;6:149–171.
- Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, *et al*. Application of 1H NMR based metabolomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. *Cancer Sci* 2009;100:782–785.
- Garcia-Canaveras JC, Donato MT, Castell JV, Lahoz A. A comprehensive untargeted metabolomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations. *J Proteome Res* 2011;10:4825–4834.
- van Ginneken V, Verhey E, Poelmann R, Ramakers R, van Dijk KW, Ham L, *et al*. Metabolomics (liver and blood profiling) in a mouse model in response to fasting: a study of hepatic steatosis. *Biochim Biophys Acta* 2007;1771:1263–1270.
- Gou X, Tao Q, Feng Q, Peng J, Sun S, Cao H, *et al*. Urinary metabolomics characterization of liver fibrosis induced by CCl<sub>4</sub> in rats and intervention effects of Xia Yu Xue Decoction. *J Pharm Biomed Anal* 2013;74:62–65.
- Griffin JL, Scott J, Nicholson JK. The influence of pharmacogenetics on fatty liver disease in the Wistar and Kyoto rats: a combined transcriptomic and metabolomic study. *J Proteome Res* 2007;6:54–61.
- Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. *Hepatology* 2008;47(2):455–60.

- Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. *Clin Liver Dis* 2008;12(4):883–900.
- Heijne WH, Kienhuis AS, van Ommen B, Stierum RH, Groten JP. Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. *Expert Rev Proteomics* 2005;2(5):767–80.
- Hyde MJ, Griffin JL, Herrera E, Byrne CD, Clarke L, Kemp PR. Delivery by Caesarean section, rather than vaginal delivery, promotes hepatic steatosis in piglets. *ClinSci (Lond)* 2010;118:47–59.
- Huang HJ, Zhang AY, Cao HC, Lu HF, Wang BH, Xie Q, et al. Metabolomic analyses of faeces reveals malabsorption in cirrhotic patients. *Dig Liver Dis* 2013;45(8):677–82.
- Imbert-Bismut F, Messous D, Thibault V, Myers RB, Piton A, Thabut D, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. *Clin Chem LabMed* 2004;42(3):323–33.
- Jepsen P, Grønbaek H. Prognosis and staging of nonalcoholic fatty liver disease. *BMJ* 2011;343:d7302.
- Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, et al. Plasma metabolomic profile in non-alcoholic fatty liver disease. *Metabolism* 2011;60:404–413.
- Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005;41(6):1313–21.
- Lian JS, Liu W, Hao SR, Guo YZ, Huang HJ, Chen DY, et al. A serum metabolomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultra performance liquid chromatography coupled to mass spectrometry plus quadruple time-of-flight mass spectrometry. *Chin Med J (Engl)* 2011;124:1367–1373.
- Li H, Wang L, Yan X, Liu Q, Yu C, Wei H, et al. A proton nuclear magnetic resonance metabolomics approach for biomarker discovery in non-alcoholic fatty liver disease. *J Proteome Res* 2011;10:2797–2806.
- Li H, Wang L, Yan X, et al. A proton nuclear magnetic resonance metabolomics approach for biomarker discovery in nonalcoholic fatty liver disease. *J Proteome Res* 2011;10:2797–2806.
- Lin X, Zhang Y, Ye G, Li X, Yin P, Ruan Q, et al. Classification and differential metabolite discovery of liver diseases based on plasma metabolic profiling and support vector machines. *J Sep Sci* 2011;34:3029–3036.
- Männistö VT, Simonen M, Hyysalo J, et al. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. *Liver Int* 2015;35(7):1853–61.
- Martinez-Granados B, Morales JM, Rodrigo JM, Del Olmo J, Serra MA, Ferrandez A, et al. Metabolic profile of chronic liver disease by NMR spectroscopy of human biopsies. *Int J Mol Med* 2011;27:111–117.
- Meikle PJ, Christopher MJ. Lipidomics is providing new insight into the metabolic syndrome and its sequelae. *Curr Opin Lipidol* 2011;22:210–215.
- Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. *Nat Rev Gastroenterol Hepatol* 2013;10:656–665.
- Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T. FibroMAX: towards anew universal biomarker of liver disease? *Expert Rev Mol Diagn* 2007;7(5):481–90.
- Newsome PN, Allison ME, Andrews PA, et al. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. *Gut* 2012;61:484–500.
- Noguchi Y, Young JD, Aleman JO, Hansen ME, Kelleher JK, Stephanopoulos G. Tracking cellular metabolomics in lipoapoptosis and steatosis-developing liver cells. *MolBiosyst* 2011;7:1409–1419.
- Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2008;28(5):503–22.
- Pastore A, Alisi A, di Giovamberardino G, et al. Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage. *Int J Mol Sci* 2014;15(11):21202–14.
- Poynard T, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, et al. Overview of the diagnostic value of biochemical markers of liverfibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. *Comp Hepatol* 2004;4:10–23.
- Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, et al. The plasma lipidomic signature of non-alcoholic steatohepatitis. *Hepatology* 2009;50:1827–1838.
- Qi SW, Tu ZG, Peng WJ, Wang LX, Ou-Yang X, Cai AJ, et al. HNMR-based serum metabolic profiling in compensated and decompensated cirrhosis. *World J Gastroenterol* 2012;18:285–290.
- Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D, Dina L. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. *J Gastrointestin Liver Dis* 2008;17(3):255–60.
- Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. *Gastroenterology* 2005;128(7):1898–906.
- Soga T, Sugimoto M, Honma M, et al. Serum metabolomics reveals g-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. *J Hepatol* 2011;55:896–905.
- Sunny NE, Kalavalapalli S, Bril F, Garrett TJ, Nautiyal M, Mathew JT, et al. Crosstalk between branched chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease. *Am J Physiol Endocrinol Metab* 2015;309(4):E311–9.
- Tanaka N, Matsubara T, Krausz KW, Patterson AD, Gonzalez FJ. Disruption of phospholipid and bile acid homeostasis in mice with non-alcoholic steatohepatitis. *Hepatology* 2012;56:118–129.
- Toye AA, Dumas ME, Blancher C, Rothwell AR, Fearnside JF, Wilder SP, et al. Subtle metabolic and liver gene transcriptional changes underlie diet induced fatty liver susceptibility in insulin-resistant mice. *Diabetologia* 2007;50:1867–1879.
- Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of non-alcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2012;10:837–858.
- Vinaixa M, Rodriguez MA, Rull A, Beltran R, Blade C, Brezmes J, et al. Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease. *J Proteome Res* 2010;9:2527–2538.
- Waldhler MC, Almstetter MF, Nurnberger N, Gruber MA, Dettmer K, Oefner PJ. Improved enantiomer resolution and quantification of free D-aminoacids in serum and urine by comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry. *J Chromatogr A* 2011;1218:4537–4544.
- Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol Cell* 1999;3:543–553.
- Wei J, Qiu de K, Ma X. Bile acids and insulin resistance: implications for treating non-alcoholic fatty liver disease. *J Dig Dis* 2009;10:85–90.
- Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. *Dtsch Arztebl Int* 2013;110:85–91.
- Yeh MM, Brunt EM. Pathology of non-alcoholic fatty liver disease. *Am J Clin Pathol* 2007;128:837–847.

Zhang A, Sun H, Dou S, Sun W, Wu X, Wang P, et al. Metabolomics study on the hepatoprotective effect of scoparone using ultra-performance liquid chromatography/electrospray ionization quadrupole time-of-flight mass spectrometry. *Analyst* 2013;138:353–361.

Zhao Y, Chen YQ, Bonacci TM, Bredt DS, Li S, Bensch WR, et al. Identification and characterization of a major liver lysophosphatidylcholine acyltransferase. *J Biol Chem* 2008;283:8258–8265.

•Alina M. Suciuc, Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 19-21 Croitorilor Street, 400162, Cluj-Napoca, Cluj, Romania, EU, email: alina.habic@yahoo.com

•Florina Romanciuc, Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, 3-5 Manastur Street, 400372, Cluj-Napoca, Cluj, Romania, EU, email; florina\_romanciuc@yahoo.com

•Carmen Socaciu, Department of Chemistry and Biochemistry, Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine, 3-5 Manastur Street, 400372, Cluj-Napoca, Cluj, Romania, EU, email: carmen.socaci@us-amvcluj.ro

•Mircea Grigorescu, Regional Institute of Gastroenterology and Hepatology, 5 Constanta Street, 400158, Cluj-Napoca, Cluj, Romania, EU, email: mdgrigorescu@yahoo.com

## Authors

•Dana A. Crisan, Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 11 Tabacarilor Street, 400139, Cluj-Napoca, Cluj, Romania, EU, email: crisan.dc@gmail.com

•Corina I. Radu, Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 19-21 Croitorilor Street, 400162, Cluj-Napoca, Cluj, Romania, EU, email: drcorinaradu@gmail.com

### Citation

Crişan DA, Radu CI, Suciuc AM, Romanciuc F, Socaciu C, Grigorescu M. Metabolomics in nonalcoholic fatty liver disease - a new technique for an open horizon. *HVM Bioflux* 2015;7(3):229-235.

### Editor

Ştefan C. Vesa

### Received

4 August 2015

### Accepted

23 August 2015

### Published Online

24 August 2015

### Funding

European Social Fund, Human Resources Development Operational Programme 2007-2013, project no. POSDRU/159/1.5/S/138776

### Conflicts/ Competing Interests

None reported